急性髓系白血病Bcl-2基因表达及其临床意义  

The Expression of Bcl-2 Gene and Its Clinical Significance in Acute Myeloid Leukemia

作　　者：向直富[1] 陈燕[1] 邹萍[1] 向建平[1] 喻东姣[1] 李慧玉[1] 李崇渔[1] 

机构地区：[1]同济医科大学血液病研究所,武汉市430022

出　　处：《临床血液学杂志》1998年第6期255-257,共3页Journal of Clinical Hematology

摘　　要：目的：探讨Bcl－2基因在急性髓系白血病（AML）中的作用。方法：应用APAAP法检测67例AML患者骨髓单个核细胞Bcl－2基因表达，半固体培养法检测CFU－L形成能力，并观察临床化疗效果。结果：发现AML患者Bcl－2基因表达显著高于正常对照组（P＜0．001），分化较成熟的M3型白血病表达率显著低于其它各亚型白血病（P＜0．01），Bcl－2蛋白表达与CFU－L形成无相关性，与患者外周血白细胞数呈正相关，高表达组CR率（47％）显著低于低表达率组（100％，P＜0．005）。结论：Bcl－2基因过度表达对AML的发生、发展有一定的作用，是造成耐药的重要原因，是判断AML预后的一个十分有用的指标。High expression of Bcl-2 protein is found in hematopoietic malignancies and implicated in development、progression and chemotherapeutic response of these diseases. Using cell culture and immunocytochemical staining methods, we investigated the biologic and clinical significance of Bcl-2 overexpression in acute myeloid leukemia (AML). The number of Bcl-2+ cells in AML was higher than that of controls (P<0.001);the percentage of Bcl-2+ cells in M3 type was lower than that in other types, (P<0.01), Bcl-2 expressien was correlated with peripheral white blood cell counts and not with the number of CFU-L. High expression of Bcl-2 was associated with a low complete resmission rate after in tensive chemotherapy (100% in cases with less than 20% positve cells, 47% in cases with more than 20% positive cells, P<0.05). Our results demonstrated that Bcl-2 expression in AML was heterogeneous; Overexpression of Bcl-2 protein is an important mechanism of chemotherapeutic resistance in AML; Clinially, the assays of Bcl-2 expression in AML have a predictive value.

关 键 词：白血病 急性 BCL-2基因 耐药 

分 类 号：R733.71[医药卫生—肿瘤]